apvma limited use permit 11859- rabies vaccine/ lyssavirus/ bats
apvma permit - rabies virus (inactivated) - vaccine
merieux inactivated rabies vaccine 2.5iu powder for injection with diluent
sanofi-aventis australia pty ltd - rabies virus, quantity: 2.5 iu - injection, powder for - excipient ingredients: albumin; neomycin - idications as at 12 july 2004: post exposure immunisation against rabies. pre-exposure immunisation in persons at special risk of contracting rabies.
verorab, powder and solvent for suspension for injection. rabies vaccine, inactivated.
sanofi pasteur - rabies virus (inactivated) strain wistar (pm/wi 38-1503-3m) - powder and solvent for suspension for injection in pre-filled syringe - rabies, inactivated, whole virus
rabipur vaccine powder and solvent for solution for injection 1ml vials
glaxosmithkline uk ltd - rabies virus inactivated - powder and solvent for solution for injection
rabipur vaccine powder and solvent for solution for injection 1ml pre-filled syringes
valneva uk ltd - rabies virus inactivated - powder and solvent for solution for injection
nobivac rabies
intervet ireland limited - inactivated rabies virus antigen suspension - suspension for injection - 2-6 international units/dose - rabies virus - cats, dogs - immunological - inactivated vaccine
hyperrab s/d (rabies immune globulin- human injection
grifols usa, llc - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 150 [iu] in 1 ml - rabies vaccine and hyperrab s/d should be given to all persons suspected of exposure to rabies with one exception: persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. hyperrab s/d should be administered as promptly as possible after exposure, but can be administered up to the eighth day after the first dose of vaccine is given. recommendations for use of passive and active immunization after exposure to an animal suspected of having rabies have been detailed by the u.s. public health service advisory committee on immunization practices (acip). [19] every exposure to possible rabies infection must be individually evaluated. the following factors should be considered before specific antirabies treatment is initiated: carnivorous wild animals (especially skunks, foxes, coyotes, raccoons, and bobcats) and bats are the animals most commonly infected with rabies and have caused most of the indigenous cases of human rabies
inactivated rabies vaccine merieux hdcv inj. sol. (pwdr. + solv.) i.m. vial + pre-filled syr.
sanofi pasteur europe s.a. - rabies virus (inactivated) ; albumin human 50 mg - powder and solvent for solution for injection - rabies virus, inactivated - rabies, inactivated, whole virus
rabisin
merial animal health limited - rabies virus glycoproteins g52 rabies virus strain - suspension for injection - per cent - rabies virus vaccine - bovine, canine, equine - food, feline, mustelids, ovine - immunological - inactivated vaccine
rabigen sag2
virbac s.a. - live attenuated rabies virus, sag2 strain - live viral vaccines - raccoon dogs (nyctereutes procyonoides); red foxes (vulpes vulpes) - for the active immunisation of red foxes and raccoon dogs to prevent infection by rabies virus.the duration of protection is of at least 6 months.